( August 27, 2025, 3:44 PM EDT) -- BOSTON — The First Circuit U.S. Court of Appeals reversed a district court’s dismissal of investors’ securities fraud class action against a global drug-development company and two of its officers, finding that the investors had plausibly alleged that the defendants “knowingly or recklessly misled investors as to problems lurking in its supply chain” of long-tailed macaques for drug-development research and safety testing, leading to an artificial rise, then drop, in stock price....